| pubmed-article:3653200 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3653200 | lifeskim:mentions | umls-concept:C0920321 | lld:lifeskim |
| pubmed-article:3653200 | lifeskim:mentions | umls-concept:C0060441 | lld:lifeskim |
| pubmed-article:3653200 | lifeskim:mentions | umls-concept:C0201734 | lld:lifeskim |
| pubmed-article:3653200 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:3653200 | lifeskim:mentions | umls-concept:C0133038 | lld:lifeskim |
| pubmed-article:3653200 | lifeskim:mentions | umls-concept:C0065133 | lld:lifeskim |
| pubmed-article:3653200 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:3653200 | pubmed:dateCreated | 1987-10-29 | lld:pubmed |
| pubmed-article:3653200 | pubmed:abstractText | The diethylaminoester of flavone acetic acid (LM985) is a new anticancer agent with curative effects against slow growing murine tumors. Thirty-one adult patients with solid tumors received a total of 57 courses of LM985 given on days 1 and 8 every 4 weeks. The drug was given as a short infusion (1-2 hr) at doses ranging from 120 to 1900 mg/sq.m/day. The dose-limiting toxicity consisted of acute expressive aphasia; this neurotoxicity usually appeared at the end of the infusion and resolved spontaneously within a few minutes to 1 hr after the end of the infusion. In some patients, neurotoxicity was avoided by reducing the infusion rate. Neurotoxicity was observed in 5 out of 6 patients receiving 960 mg/sq.m over 1 hr and in 3 out of 3 patients receiving 1900 mg/sq.m over 2 hr. The drug did not induce any significant myelosuppression. Other side-effects were very mild and consisted mainly of occasional nausea and/or vomiting at all dose levels. One patient with breast cancer resistant to several hormonal and chemotherapy regimens had stable disease for 6 months. LM985 was detected in plasma in very small concentrations (0-2.5 micrograms/ml) but there was extensive formation of flavone acetic acid (peak concentration ranging between 8.3 and 64 micrograms/ml). A dose of 1500 mg/sq.m on days 1 and 8 every 4 weeks could be recommended for phase II studies with LM985; however, since LM985 is a prodrug of flavone acetic acid, phase II studies with LM985 should not be activated prior to the completion of the ongoing phase I trials with flavone acetic acid, which may be devoid of the acute toxicity of LM985. | lld:pubmed |
| pubmed-article:3653200 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3653200 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3653200 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3653200 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3653200 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3653200 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3653200 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3653200 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:3653200 | pubmed:issn | 0277-5379 | lld:pubmed |
| pubmed-article:3653200 | pubmed:author | pubmed-author:PeetersBB | lld:pubmed |
| pubmed-article:3653200 | pubmed:author | pubmed-author:KenisYY | lld:pubmed |
| pubmed-article:3653200 | pubmed:author | pubmed-author:AbramsJJ | lld:pubmed |
| pubmed-article:3653200 | pubmed:author | pubmed-author:GérardBB | lld:pubmed |
| pubmed-article:3653200 | pubmed:author | pubmed-author:CrespeigneNN | lld:pubmed |
| pubmed-article:3653200 | pubmed:author | pubmed-author:DodionP FPF | lld:pubmed |
| pubmed-article:3653200 | pubmed:author | pubmed-author:Van BerchemCC | lld:pubmed |
| pubmed-article:3653200 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3653200 | pubmed:volume | 23 | lld:pubmed |
| pubmed-article:3653200 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3653200 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3653200 | pubmed:pagination | 837-42 | lld:pubmed |
| pubmed-article:3653200 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:3653200 | pubmed:meshHeading | pubmed-meshheading:3653200-... | lld:pubmed |
| pubmed-article:3653200 | pubmed:meshHeading | pubmed-meshheading:3653200-... | lld:pubmed |
| pubmed-article:3653200 | pubmed:meshHeading | pubmed-meshheading:3653200-... | lld:pubmed |
| pubmed-article:3653200 | pubmed:meshHeading | pubmed-meshheading:3653200-... | lld:pubmed |
| pubmed-article:3653200 | pubmed:meshHeading | pubmed-meshheading:3653200-... | lld:pubmed |
| pubmed-article:3653200 | pubmed:meshHeading | pubmed-meshheading:3653200-... | lld:pubmed |
| pubmed-article:3653200 | pubmed:meshHeading | pubmed-meshheading:3653200-... | lld:pubmed |
| pubmed-article:3653200 | pubmed:meshHeading | pubmed-meshheading:3653200-... | lld:pubmed |
| pubmed-article:3653200 | pubmed:meshHeading | pubmed-meshheading:3653200-... | lld:pubmed |
| pubmed-article:3653200 | pubmed:meshHeading | pubmed-meshheading:3653200-... | lld:pubmed |
| pubmed-article:3653200 | pubmed:meshHeading | pubmed-meshheading:3653200-... | lld:pubmed |
| pubmed-article:3653200 | pubmed:year | 1987 | lld:pubmed |
| pubmed-article:3653200 | pubmed:articleTitle | Clinical and pharmacokinetic phase I trial with the diethylaminoester of flavone acetic acid (LM985, NSC 293015). | lld:pubmed |
| pubmed-article:3653200 | pubmed:affiliation | Service de Médecine Interne, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Brussels, Belgium. | lld:pubmed |
| pubmed-article:3653200 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3653200 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
